Table 1.

Randomized studies of bevacizumab-based treatment for prognostic and predictive analyses

TrialPatient PopulationRegimenPrimary End PointResult for Primary End PointPlasma Samples
AVF210712Previously untreated mCRC (n = 813)IFL with bevacizumab (5 mg/kg q2w) or placeboOS20.3 vs. 15.6 months (HR, 0.66; P < 0.001)n = 384
E459914Newly diagnosed stage IIIb (malignant plural effusion) or stage IV or recurrent nonsquamous NSCLC (N = 878)Carboplatin and paclitaxel with bevacizumab (15 mg/kg q3w) or placeboOS12.3 vs. 10.3 months (HR, 0.79; P = 0.003)n = 166
AVAiL36Stage IIIb (supraclavicular lymph node metastasis or malignant pleural effusion or pericardial effusion) or stage IV or recurrent nonsquamous NSCLC (N = 1,043)Cisplatin and gemcitabine with low-dose bevacizumab (7.5 mg/kg q3w), high-dose bevacizumab (15 mg/kg q3w), or placeboUnstratified PFSLow-dose: 6.7 vs. 6.1 months (HR, 0.75; P = 0.003); High-dose: 6.5 vs. 6.1 months (HR, 0.82; P = 0.03)n = 882
AVOREN15Previously untreated, predominantly clear cell mRCC (N = 649)Interferon alfa-2a with bevacizumab (10 mg/kg q2w) or placeboPFSa10.2 vs. 5.4 months (HR, 0.63, P = 0.0001)n = 384
AVF293830Previously untreated mRCC of predominantly clear cell histology with prior nephrectomy (N = 104)Bevacizumab (10 mg/kg q2w) with erlotinib or placeboPFS9.9 vs. 8.5 months (HR, 0.86; P = 0.58)n = 103

Abbreviations: IFL, irinotecan with bolus fluorouracil and leucovorin; q2w, every 2 weeks, q3w, every 3 weeks.

  • aThe primary end point was OS; however, the preplanned final analysis of PFS was deemed acceptable for regulatory submission.